A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02962141|
Recruitment Status : Completed
First Posted : November 11, 2016
Last Update Posted : August 7, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Arterial Disease Fistula||Device: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter Device: Balloon Dilatation Catheter||Not Applicable|
To evaluate the safety and efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) compared with the Balloon Dilatation catheter (OHICHO II) for the treatment of Arteriovenous Fistulae Stenosis in patients undergoing hemodialysis.
This is a prospective, multi-center, randomized controlled, open-label, superiority study. A total of 160 subjects will be enrolled from 10 sites in China. All subjects enrolled will be randomly assigned to the test group (APERTO group, n=80) and the control group (OHICHO II group, n=80) with randomized allocation ratio of 1:1. Subjects in the test group and the control group will be treated with APERTO OTW or OHICHO II respectively.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||161 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Safety and Efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis: A Prospective, Multicenter, Randomized, Controlled Clinical Study|
|Study Start Date :||October 2016|
|Actual Primary Completion Date :||January 2018|
|Actual Study Completion Date :||June 2019|
Experimental: APERTO OTW group
in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
Device: Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Other Name: APERTO OTW
Active Comparator: OHICHO II group
in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
Device: Balloon Dilatation Catheter
Other Name: OHICHO II
- Primary patency rate of the target lesion [ Time Frame: at 6 month post procedure ]
Primary patency is defined as freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) ≤ 2.0 and freedom from clinically-driven target lesion revascularization (CD-TLR).
Restenosis is defined as PSVR> 2.0 determined by independent DUS laboratory. Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention in target lesion (+/-5mm proximal or distal of the target lesion) determined by DUS due to clinical symptoms or dialysis indicators showing that it is unable to perform dialysis.
- Device Success [ Time Frame: intraoperative ]Device Success is defined as ability of the Device to be delivered, inflated at pressure ≤ RBP, and retrieved from the Target Lesion without burst.
- Technical Success [ Time Frame: intraoperative ]Technical Success is defined as the residual stenosis of the lumen diameter ≤ 30% after treatment with either APERTO OTW or OHICHO II (compared with the referred vessel diameter of the nearest veins with no aneurysm).
- Clinical Success [ Time Frame: at 1 month ]Clinical Success is defined as improvement in hemodialysis access function and resumption of normal dialysis for at least one dialysis session after the index procedure.
- Procedural Success [ Time Frame: at 1 month ]Procedural Success is defined as technical success without the occurrence of MAE during the hospitalization or day of treatment (MAE defined here as: death, stroke, thrombotic occlusion, allergic reaction, pulmonary events (including pulmonary edema)
- MAE rates (death or stroke) [ Time Frame: at 1 month, 3 months, 6 months, and 12 months post procedure. ]
- The diameter stenosis rate in target lesion [ Time Frame: at 6 months post procedure ]The diameter stenosis (%)=100% × (1-(MLD/RVD))
- Clinical-driven Target Lesion Revascularization (CD-TLR) [ Time Frame: in1st, 3rd, 6th, 12th month post operation ]CD-TLR is defined as any re-intervention in target lesion (+/-5mm proximal or distal of the target lesion) determined by DUS due to clinical symptoms or dialysis indicators showing that it is unable to perform dialysis.
- Clinical-driven Target Shunt Revascularization (CD-TSR) [ Time Frame: in 1st, 3rd, 6th, 12th month post operation ]
Target Shunt is defined as the reflux vein, which is from the anastomotic stoma of native arteriovenous fistula (AVF) to the distal end of the subclavian vein.
CD-TSR is defined as any re-intervention in target lesion due to clinical symptoms or inability to perform dialysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients must meet all of the following criteria:
- Age ≥ 18 years and ≤ 75 years, male or female.
- Patient or legally authorized representative can understand the purpose of this clinic trial. He or She volunteers to participate in this trial and can provide written informed consent, and is willing to accept the scheduled follow-up in specific time points.
- Angiography, ultrasound or clinical diagnosis shows that patients have hemodialysis access dysfunction due to stenosis lesions.
Patients with indications of the percutaneous endovascular therapy, that is, the AVF stenosis is related to hemodynamics and ≥ 50%, and with any of the following clinical and physiological abnormalities (referred to NKF-K/DOQI guideline definitions):
- Thrombosis in the AVF;
- Elevated venous pressure during dialysis
- Obvious abnormality in recirculation measurements
- Abnormal physical examination findings
- Unexplained decreases in dialysis dose
- Decreased access flow
- Target lesion is a de novo or restenosis. The number of target lesions is 1.
- Target lesion consists of a single lesion or a multiple lesions with target lesion length ≤ 40 mm.
- Target lesion(s) is located in the reflux vein which is from the anastomosis of native arteriovenous fistula (AVF) to the distal end of subclavian vein, except the anastomosis of native AVF.
- If patient has non-target lesion, it must be successfully treated using PTA before treating target lesion.
- Reference vessel diameter of target lesion ≥ 4.0 mm and ≤ 7.0 mm by visual estimate (determined by angiography or DUS).
- Hemodialysis access previously used (mature AVF) can no longer be successfully used due to insufficient shunt flow volume caused by local lumen stenosis.
Patients will be excluded if any of the following conditions applies:
- Patients who have participated in another investigational drug or device trial.
- Patients who have been enrolled in this trial previously.
- Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women.
- Any major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days prior to the procedure.
- Any planned major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days of entry into this study
- Immature AVF, which cannot be used for Dialysis or has not been used successfully due to insufficient lumen diameter to ensure successfully puncture and insufficient shunt flow volume.
- Patients with AVG.
- AVF has been previously implanted with stent.
- Lesion in AVF has been previously treated with DEB.
- Target lesion is located in the anastomosis of native AVF.
- Known allergies or intolerance to Paclitaxel or contrast medium.
- Life expectancy < 1 year
- Patients with comitans systemic lupus erythematosus and ANCA associated vasculitis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02962141
|Hainan General Hospital|
|Haikou, Hainan, China|
|The First Hospital of Hebei Medical University|
|Shijiazhuang, Hebei, China|
|The Third Xiangya Hospital of Central South University|
|Changsha, Hunan, China|
|The First Affiliated Hospital of Nanchang University|
|Nanchang, Jiangxi, China|
|West China Hospital, Sichuan University|
|Chengdu, Sichuan, China|
|Sir Run Run Shaw Hospital School of Medicine, Zhejiang University|
|Hangzhou, Zhejiang, China|
|The First Hospital of Zhejiang Province|
|Hangzhou, Zhejiang, China|
|Beijing Tongren Hospital, Capital Medical University|
|Longhua Hospital Shanghai University of Tranditional Chinese Medicine|
|Principal Investigator:||Qizhuang Jin, professor||Peking University First Hospital|
|Responsible Party:||ZhuHai Cardionovum Medical Device Co., Ltd.|
|Other Study ID Numbers:||
|First Posted:||November 11, 2016 Key Record Dates|
|Last Update Posted:||August 7, 2019|
|Last Verified:||August 2019|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
drug eluting balloon, Arteriovenous Fistulae
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathological Conditions, Anatomical
Arterial Occlusive Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action